Document 0884
 DOCN  M9650884
 TI    [Effects of Shenmai injection on immune function in stomach cancer
       patients after chemotherapy]
 DT    9605
 AU    Lin SY; Liu LM; Wu LC; Zhejiang provincial Hospital of TCM, Hangzhou.
 SO    Chung Kuo Chung Hsi I Chieh Ho Tsa Chih. 1995 Aug;15(8):451-3. Unique
       Identifier : AIDSLINE MED/96147895
 AB    Sixty-three cases with stomach cancer were randomized and observed, the
       results showed that the count of T lymphocytes in chemotherapy combined
       with Shenmai injection (SMI) group increased, while in control group it
       decreased, the difference was significant (P < 0.05). The results also
       indicated that the count of OKT4 cells and the ratio of OKT4/OKT8
       decreased after chemotherapy, but in SMI group both parameters increased
       in advence which were higher in the 4th week after chemotherapy than
       that before chemotherapy. However, the count of OKT1 cells and the ratio
       of OKT4/OKT8 were still in low level. Serum interleukin-2 receptor
       (sIL-2R) level also decreased (P < 0.05), while activities of natural
       killer cell (NK) and lymphokine activated killer cell (LAK) level
       increased (P < 0.05) in SMI group. Although the sIL-2R level had no
       change, both NK and LAK level decreased in control group. In addition,
       the difference of IgA, IgM, IgG level were not significant between these
       two groups. This suggested that SMI might improve human immune function
       to facilitate the chemotherapy of patients with stomach cancer.
 DE    Adenocarcinoma/DRUG THERAPY/*IMMUNOLOGY  Adjuvants,
       Immunologic/*PHARMACOLOGY  Adult  Aged  Antineoplastic Agents/ADVERSE
       EFFECTS  Comparative Study  CD4-CD8 Ratio  Drug Combinations  Drugs,
       Chinese Herbal/*PHARMACOLOGY  English Abstract  Female  *Ginseng  Human
       Injections, Intravenous  Killer Cells, Natural/IMMUNOLOGY  Male  Middle
       Age  Receptors, Interleukin-2/METABOLISM  Stomach Neoplasms/DRUG
       THERAPY/*IMMUNOLOGY  CLINICAL TRIAL  JOURNAL ARTICLE  RANDOMIZED
       CONTROLLED TRIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).